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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive and irreversible chronic inflammatory
disease of the lung. The nature of the immune reaction in COPD raises the possibility that IL-17 and related
cytokines may contribute to this disorder. This study analyzed the expression of IL-17A and IL-17F as well as the
phenotype of cells producing them in bronchial biopsies from COPD patients.
Methods: Bronchoscopic biopsies of the airway were obtained from 16 COPD subjects (GOLD stage 1-4) and 15
control subjects. Paraffin sections were used for the investigation of IL-17A and IL-17F expression in the airways by
immunohistochemistry, and frozen sections were used for the immunofluorescence double staining of IL-17A or IL-
17F paired with CD4 or CD8. In order to confirm the expression of IL-17A and IL-17F at the mRNA level, a
quantitative RT-PCR was performed on the total mRNA extracted from entire section or CD8 positive cells selected
by laser capture microdissection.
Results: IL-17F immunoreactivity was significantly higher in the bronchial biopsies of COPD patients compared to
control subjects (P < 0.0001). In the submucosa, the absolute number of both IL-17A and IL-17F positive cells was
higher in COPD patients (P < 0.0001). After adjusting for the total number of cells in the submucosa, we still found
that more cells were positive for both IL-17A (P < 0.0001) and IL-17F (P < 0.0001) in COPD patients compared to
controls. The mRNA expression of IL-17A and IL-17F in airways of COPD patients was confirmed by RT-PCR. The
expression of IL-17A and IL-17F was co-localized with not only CD4 but also CD8, which was further confirmed by
RT-PCR on laser capture microdissection selected CD8 positive cells.
Conclusion: These findings support the notion that Th17 cytokines could play important roles in the pathogenesis
of COPD, raising the possibility of using this mechanism as the basis for novel therapeutic approaches.
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Introduction
Chronic obstructive pulmonary disease (COPD), a pro-
gressive and irreversible chronic inflammatory disease of
the lung caused predominantly by cigarette smoking, is
one of the most important causes of mortality globally
[1]. The inflammatory response in the lungs of COPD
patients has been found to be strongly linked to tissue
destruction and alveolar airspace enlargement, which
lead to disease progression [2].
The inflammatory response reflects both the innate
immune response to cigarette smoke exposure in the
form of cellular infiltration by neutrophils and macro-
phages, as well as the adaptive immune response invol-
ving B and T cells, which is intimately linked with
innate immunity [3]. COPD is marked by the accumula-
tion of both CD4
+ and CD8
+ T cells in the alveolar
walls, with CD8
+ cells predominating [4]. Recent find-
ings concerning the innate and acquired immune
responses in COPD have led to the suggestion that
there is an autoimmune component to its pathogenesis.
This notion is supported by the similarity of pathophy-
siological characteristics between COPD and several
autoimmune diseases, including rheumatoid arthritis
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ance of necrotic cells and subcellular particles, a defi-
ciency of regulatory T cells and the presence of
autoantibodies and autoreactive T cells [5].
The nature of the immune reaction in COPD raises
the possibility that IL-17 and related cytokines may
contribute to this disorder. Th17, a newly described
s u b s e to fTc e l l s ,w e r es u g g e s t e dt op l a yar o l ei nR A
and psoriasis. To date six IL-17 family members
(IL-17A, IL-17B, IL-17C, IL-17D, IL-17E/IL-25 and IL-
17F) and five receptors (IL-17RA, IL-17RB, IL-17RC,
IL-17RD and IL-17RE) have been identified, which are
conserved in rodents and humans [6]. IL-17A and IL-
17F display high sequence homology and can be
secreted as homodimers, as well as IL-17A/F heterodi-
mers, by both mouse and human cells [7,8]. Although
IL-17 has been closely associated with a subset of T
helper cells known as Th17 cells, gδ T cells, natural
killer [9] T cells and neutrophils have also been shown
to produce IL-17A in the lung [10]. IL-17 secretion
triggers production of numerous chemokines, resulting
in neutrophil and macrophage recruitment and subse-
quent pathogen clearance, thus IL-17 mediates cross-
talk between the adaptive and innate immune systems,
allowing for orchestration of an effective immune
response [10,11].
Numerous studies demonstrated the importance of IL-
17 in the context of autoimmunity [10], however little is
known about IL-17 production in COPD. A recent
study showed that IL-17A could induce production of
mucin (MUC)5AC in human bronchial epithelial cells
[12], supporting the potential involvement of IL-17A in
the phenotypic manifestations of COPD. In addition,
transgenic over expression of Il-17 in the alveoli of mur-
ine lung induces lung inflammation with a COPD-like
phenotype [13]. Aside from IL-17A, IL-17F mediated
pathways might also provide a link between local activa-
tion of T cells and sustained accumulation of neutro-
phils in inflamed airways [14]. A case-control study
demonstrates an association between an IL-17F gene
polymorphism and chronic inflammatory lung diseases,
including bronchial asthma and COPD, suggesting that
IL-17F may be critically involved in the pathogenesis of
chronic inflammatory lung diseases [15].
A well-known hallmark ofC O P Di st h a ti ti sr e l a -
tively unresponsive to treatment with steroids. Corti-
costeroids alone have little impact on the cellular
inflammation or increased protease burden observed in
COPD [16]. In addition, whereas exogenous steroids
are able to suppress cytokine production in cells col-
lected from non-diseased airways, the same cell types
from patients with COPD are resistant to steroid treat-
ment [17]. In this regard, it is of interest that IL-17
expression has been associated with diminished steroid
responsiveness [15]. Moreover, there has been a recent
suggestion that autoimmunity plays a role in the
pathogenesis of COPD [5] and given the increased
expression of IL-17 in certain autoimmune diseases
[10], this further raises the possibility of its involve-
ment in the pathogenesis of COPD.
In the present study, we analyzed the expression of IL-
17A and IL-17F as well as the phenotype of cells produ-
cing them in the bronchial biopsies from COPD patients
using immunohistochemistry, immunofluorescence
staining, laser capture microdissection and quantitative
reverse transcription-PCR. For the first time, we demon-
strated the IL-17A and IL-17F expression in CD4
+ and
especially in CD8
+ T cells in the airways of COPD
patients. We also showed higher expression of these
cytokines in COPD patients compared to control sub-
jects. This study supports the notion that IL-17 is a
pathogenetic element of COPD and suggests the possi-
bility that a strategy of targeting IL-17 as a therapeutic
target may be of value in this disease.
Methods
Subjects
Bronchoscopic biopsies from the subsegmental bronchi
were obtained from 16 clinical diagnosis of COPD
patients (GOLD stage 1-4) and 15 control subjects using
published techniques [18] at the Montreal Chest Insti-
tute of the McGill University Health Centre and Laval
Hospital, Canada. The COPD patients were eligible for
this study if they met the following criteria: age ≥ 40
and ≤ 75 years; smoking history (≥ 10 pack-years); post-
bronchodilator FEV1≥ 25% of predicted value and post-
bronchodilator FEV1/forced vital capacity (FVC) ≤ 0.70;
no history of asthma, atopy (as assessed by an allergy
skin prick test during screening) or any other active
lung disease. Patients on home oxygen or with raised
carbon dioxide tension (>44 mmHg), a1-antitrypsin defi-
ciency, recent exacerbation (in the last 4 weeks), uncon-
trolled medical condition or hypersensitivity to inhaled
corticosteroids and bronchodilators were not eligible for
the study. The experimental procedures were performed
with ethical approval from the Research Ethics Boards
of the McGill University Health centre and Laval Uni-
versity (Table 1).
Processing of airway biopsies
Duplicate biopsy specimens from each case were imme-
diately fixed in 4% paraformaldehyde for 4 h, and then
treated in PBS/DEPC for overnight at 4°C. One speci-
men was dehydrated in alcohol and xylol and embedded
in paraffin for immunohistochemistry, which was carried
out on 5 μm thick sections. The second was snap-frozen
in liquid nitrogen-cooled isopentane for immunofluores-
cence (6 μm thick), laser capture microdissection and
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thick).
Immunohistochemistry
Paraffin-embedded specimens were deparaffinized in
xylene, rehydrated through a decreasing ethanol gradi-
ent, and rinsed in PBS. Antigen unmasking was per-
formed with 10 Mm citrate buffer pH 6 and following
with 0.2% Triton X100 in PBS. Endogenous peroxidase
activity was blocked with 6% hydrogen peroxide for 30
min at room temperature. The slides were washed and
pretreated with universal blocking solution (Dako, Car-
pinteria, USA). Slides were incubated overnight at 4°C
using diluted goat anti-human IL-17A (AF317-NA, R&D
Systems) or IL-17F (AF1335, R&D Systems) polyclonal
antibodies or relevant isotype controls (AB-108-C, R&D
Systems). The slides were rinsed and incubated with a
biotinylated secondary antibody for 30 min at room
temperature. After washing in PBS, the complex Strepta-
vidin/HorseRadish Peroxidase (Vector) was applied for
30 min at room temperature. The reaction result was
visualized with DAB/hydrogen peroxide (DAB Kit,
Dako). The sections were finally rinsed in distilled
water, lightly stained with hematoxylin, dehydrated,
cleared, and cover slipped. Sample processed the same
isotypes as primary antibody served as negative control.
Immunofluorescence double staining
After permeabilization in PBS-Triton X100 0.2% for 10
min at room temperature, the sections were blocked
with the universal blocking solution (Dako) for 30 min.
The sections for double labeling with IL-17A or IL-17F
paired with CD4 and CD8 respectively were incubated
with diluted goat anti-human IL-17A antibody (1:100)
or IL-17F antibody (1:200) (R&D Systems) paired with
mouse anti-human CD4 antibody (1:40) (VP-C319, Vec-
tor), CD8 antibody (1:120) (M7103, Dako) or relevant
isotype controls (MAB002, R&D Systems) for overnight
at 4°C. After rinsing with PBS, the sections were then
reacted with Alexa 488-conjugated rabbit anti-goat IgG
and Alexa 555-conjugated rabbit anti-mouse IgG (Mole-
cular probes Inc., Eugene, OR), diluted together at 1:300
in PBS for 30 min. The sections were then cover slipped
with PermaFluor Aqueous mounting medium (Thermo;
Pittsburgh, PA). Fluorescence immunolabeling signals
were detected by a fluorescence microscope (Olympus
BX51TF, Japan).
Laser Capture Microdissection
Laser capture microdissection (LCM) was performed
using the PixCell II apparatus (Arcturus Biosciences,
Moutain View, CA) in accordance with the manufac-
turer’s instructions. A fast immunohistochemistry
staining was performed on frozen tissue sections (10
μm). Briefly, after treated with blocking solution
(Dako) and 0.5% Triton-X100, the sections were incu-
bated with mouse anti-human CD8 (Ced) for 10 min
and following with biotinylated rabbit anti-mouse IgG
(Dako) for 10 min. Then the sections were incubated
with streptavidin-HRP for 8 min and visualized with
DAB/hydrogen peroxide. After counterstaining with
haematoxyline, sections were dehydrated in increasing
ethanol gradient and 100% xylene immediately before
performing LCM. The labeled cells were captured by
LCM. For each sample, LCM was performed on 8 to
10 tissue sections yielding approximately 300 to 500
cells per section. The sections were pooled to yield
approximately 3000 to 5000 cells per sample. As CD4
+
cells were already known to express IL-17 [17,19], this
part of study was done to confirm the expression of
IL-17 in CD8
+ cells.
RNA Isolation and Quantitative Reverse Transcription-PCR
Total RNA was isolated using the RNeasy Micro RNA
isolation kit (Qiagen) from LCM samples or RLT lysis
buffer (Qiagen) with 1% b-mercaptoethanol treated air-
way tissues from entire frozen sections. Complementary
DNA was synthesized by reverse transcription (RT) of
total isolated RNA (Superscript II First Strand Synthesis,
Invitrogen, Carlsbad, CA). Quantitative RT-PCR for IL-
17A, IL-17F and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) as performed using a Step One Plus
Thermal Cycler (Applied Biosystems, Foster City, CA)
with Power SYBR Green PCR Master Mix (Applied
Table 1 Clinical characteristics of COPD and control
subjects
COPD Controls
Number 16 15
Age 53 ± 6 48 ± 9
Male/Female 10/6 11/4
Current/ex-smokers 7/8 0/3
Post-BD FEV1% predicted 60 ± 18 95 ± 12
TLCO% 60 ± 15 100 ± 20
GOLD Stage
I2 -
II 8 -
III-IV 6 -
Respiratory Medication
SABD 13 -
LABD 4 -
ICS 5 -
Combination (LABD+ICS) 3 -
Theophylline 0 -
Data are presented as mean ± SD. BD, bronchodilator; FEV1, forced expiratory
volume in 1s; TLCO, Transfer Factor of the Lung for Carbon Monoxide; SABD,
short-acting bronchodilators; LABD, long-acting bronchodilators; ICS, inhaled
corticosteroids.
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genes of IL-17A (174 bp), IL-17F (200 bp) and GAPDH
(139 bp) are as follows:
IL-17A forward: 5’-CATCCATAACCGGAATAC-
CAATA-3’; IL-17A reverse: 5’-TAGTCCACGTTCC-
CATCAGC-3’; IL-17F forward: 5’-GTGCCAGGAGG
TAGTATGAAGC-3’; IL-17F reverse: 5’-ATGTCTTCC
TTTCCTTGAGCATT-3’;G A P D Hf o r w a r d :5 ’-AGT-
CAACGGATTTGGTCGTATT-3’; GAPDH reverse: 5’-
ATGGGTGGAATCATATTGGAAC-3’;
Analysis for immunohistochemistry
Immunostained cells in the airway submucosa were
counted at a magnification of 400. The area of submu-
cosa was measured by using the software Image Pro 6.2
(MediaCybernetics, Bethesda, USA). The final result was
expressed as the number of positive cells/mm
2.T h e
number of cells was corrected for the total number of
cells by counting the number of nuclei in the submu-
cosa. The positive staining area of IL-17F in airway
epithelium was measured and the results were presented
as the percentage of positive area in total epithelium
area.
Statistical analysis
Data were expressed as median (range). The mean value
of IL-17A (in positive cells/mm
2) and IL-17F (in positive
cells/mm
2 or positive area percentage) in the COPD
patients and in the normal controls were analyzed using
Mann-Whitney U test. Probability values of P <0 . 0 5
were considered significant. Data analysis was performed
by using the Graphpad Instat 3 software (GraphPad
Software, La Jolla, California).
Results
IL-17A and IL-17F expression is increased in airways of
COPD patients
We observed IL-17A and IL-17F expression in the air-
ways of control subjects and COPD patients by immu-
n o h i s t o c h e m i s t r y .W ew e r eo n l ya b l et od e t e c t
occasional immunoreactivity of IL-17A expression in
epithelium. In contrast, we observed considerable
staining for IL-17F in airway epithelium (Figure 1A),
which was greater in the airways of COPD subjects
compared to controls (25 (5-65) % vs. 11 (0-32) %, P <
0.0001) (Figure 1B). In the submucosa, both IL-17A
and IL-17F positive cells were observed (Figure 1A),
and the absolute number of cells expressing both of
these cytokines was higher in COPD subjects than in
control subjects (IL-17A
+: 199 (70-310) vs. 49 (0-150);
IL-17F
+: 287 (195-501) vs. 67 (0-203); P < 0.0001) (Fig-
ure 1C). There was also some immunoreactivity of IL-
17A and F in the endothelial site of few blood vessels
in some sections.
More submucosal cells expressed IL-17A and IL-17F in
airways of COPD patients
As expected, we found that the number of submucosal
cells in the airways of COPD subjects was greater than in
control subjects (2371 (509-5011) vs. 1025 (391-4087),
P < 0.001) (Figure 2A). We therefore evaluated the rela-
tive number of IL-17A
+ and IL-17F
+ cells taking in
consideration the total number of submucosal cells. Simi-
larly there was greater number of cells positive for both
I L - 1 7 Aa n dI L - 1 7 Fi nC O P Ds u b j e c t sc o m p a r e dt oc o n -
trols (IL-17A: 8 (6-14) % vs. 3 (0-7) %, P < 0.0001; IL-
17F: 10 (4-28) % vs. 4 (0-14) %, P < 0.0001) (Figure 2B).
IL-17A and IL-17F expression is not regulated on
transcriptional level
To further investigate the expression of IL-17A and IL-
17F in COPD, we performed quantitative RT-PCR on
frozen airways sections of COPD patients. As with pro-
tein expression, the expression of IL-17A and IL-17F
mRNA was also detected in airways of COPD patients
(Figure 3A). Although there was trend for IL-17F to be
more increased in COPD patients compared to control,
the quantification of IL-17A and IL-17F mRNA in
COPD patients was not statistically higher compared to
control (Figure 3B).
IL-17A and IL-17F expressed in CD4
+ and CD8
+ T cells
To investigate the relationship of IL-17A&F to T cells,
we used double immunofluorescence staining with anti-
bodies to IL-17A or IL-17F and antibodies to CD4
+ or
CD8
+ T cells. In the airways of COPD subjects, both
CD4
+ and CD8
+ T cells expressed IL-17A and IL-17F
(Figure 4A). To our knowledge, this is the first demon-
stration that CD8
+ cells produce IL-17A and IL-17F in
COPD. Furthermore, we estimated the percentage of
CD4
+ and CD8
+ T cells that express IL-17A and IL-17F
as well as the percentage of IL-17A
+ and IL-17F
+ cells
that co-express T cell markers. In COPD patients, simi-
lar percentage of CD4
+ and CD8
+ T cells that express
IL-17A and IL-17F was observed (Figure 4B). While in
total IL-17A
+ cells, the percentage of IL-17A positive
cells that co-express CD8 immunoreactivity was signifi-
cantly higher than that expressing CD4
+ T cells (16.0 ±
4.3% vs. 3.4 ± 2.0%, P < 0.05, Figure 4C). A similar
trend was also observed in total IL-17F
+ cells (15.8 ±
8.8% vs. 6.6 ± 4.3%, Figure 4C). We further confirmed
this finding using LCM to select CD8
+ T cells for the
detection of expression of IL-17 mRNA by RT-PCR
(Figure 4D).
Discussion
This study aimed to investigate the possibility that the
Th17 cytokines including IL-17A and IL-17F are
involved in the pathogenesis of COPD. Using bronchial
Chang et al. Respiratory Research 2011, 12:43
http://respiratory-research.com/content/12/1/43
Page 4 of 10biopsies from COPD patients, we found evidence that
the expression of both IL-17A and IL-17F is increased
in the airways of COPD subjects in both inflammatory
cells as well as the airway epithelium. These observa-
tions add to the growing evidence, which suggests that
Th17 cytokines play a significant role in this disease.
Using immunocytochemistry, we consistently detected
increased expression of both IL-17A and IL-17F in the
airways of COPD patients compared to controls. Both
cytokines were present to a much greater extent than in
controls (Figure 1). The pattern of expression appeared
to differ between the two cytokines in that we detected
Figure 1 IL-17A and IL-17F expression in COPD patients. (A) Immunohistochemistry, positive staining appears brown color. Magnification, 100 ×.
Scale bar = 50 μm. (B) IL-17F expression in epithelium of airways of COPD patients. IL-17F positive area in epithelium was measured as outlined in
text. (C) IL-17A and IL-17F expression in submucosa of airways of COPD patients. Absolute IL-17A
+ and IL-17F
+ positive cells in submucosa were
counted. Results are expressed as median (range), n = 15 and 16 subjects for controls and COPD patients respectively. ***P < 0.0001.
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very little in controls. However, the best control group
is smokers without COPD, but we were unable to obtain
such a group.
The detection of considerable level of IL-17F in the
epithelium is of interest given the potential importance
of the epithelium in the inflammatory process of COPD
[20]. When stimulated with pro-inflammatory mediators,
the airway epithelium releases chemoattractants CXCL1
(GRO-a), CXCL5 (ENA-78), CXCL6 (GCP-2), CXCL8
(IL-8) and CCL5 (RANTES) [21,22]. Overexpression of
IL-17F predominantly expressed in bronchial epithelial
cells has also been reported in ovalbumin challenged
mice [23]. In addition, overexpression of IL-17F in mur-
ine lung epithelium leads to infiltration of lymphocytes
and macrophages and mucus hyperplasia [24]. Taken
together, these observations suggest the possibility that
IL-17F contributes to amplification of the ongoing
inflammatory processes not only through the recruit-
ment and activation of specific subset of inflammatory
cells, but by prolonging their survival in the airway.
Our results contrast to some degree with the recent
report of Di Stefano et al [25] who found evidence of
increased production of IL-17A but not IL-17F in the
bronchial submucosa of COPD patients. Furthermore,
they detected expression of both IL-17A and IL-17F in
the epithelium but failed to detect a difference between
controls and COPD patients. The discrepancy between
their results and ours may reflect differences in patient
selection or technique. Notwithstanding these differ-
ences, reports to date consistently support the notion
that there is increased expression of IL-17A and IL-17F
Figure 2 Percentage of IL-17A
+ and IL-17F
+ cells in airway submucosal cells of COPD patients. (A) Submucosal cells in airways of COPD
patients. (B) Percentage of IL-17A
+ and IL-17F
+ cells in airway submucosal cells of COPD patients. Results are expressed as median (range), n =
15 and 16 subjects for controls and COPD patients respectively. **P < 0.001, ***P < 0.0001.
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tance of Th17 cytokines in this disease.
A potential explanation of increased expression of IL-
17 in COPD airways is that this may be simply a reflec-
tion of the presence of greater numbers of submucosal
cells. Indeed, consistent with previous studies, we
detected increased cell number in the airway submucosa
of COPD patients (Figure 2). However, even after
accounting for this, we still detected significant differ-
ences between COPD and control, as the proportion of
submucosal cells expressing IL-17A and IL-17F in
COPD subjects was greater than that in controls. To
further explore the basis for this increased expression by
submucosal cells, we undertook studies of cytokine
expression at the mRNA level. As expected, we were
able to consistently detect evidence of IL-17A and IL-
17F mRNA in the airways of COPD subjects (Figure 3).
However the quantification results showed that the
mRNA expression of IL-17A and F was not statistically
different between COPD patients and controls, suggest-
ing that there is a discrepancy between mRNA and pro-
tein expression for IL-17A and F in COPD patients and
that increased IL-17A expression in COPD patients is
regulated at translational level. To refine this
observation, we employed a combination of immunocy-
tochemistry and laser capture microscopy. Double
immunostaining demonstrated detection of IL-17A and
IL-17F not only in CD4
+ cells as expected, but also in
CD8
+ cells (Figure 4). The high percentage of IL-17A
and IL-17F expressing CD immunoreactivity suggested
that CD8
+ T cells are major source of these cytokines
particularly in COPD [4]. We then used laser capture
microscopy to select regions of the airway that were
positive for either CD4 or CD8 by immunostaining from
which we extracted the RNA to confirm that both CD4
+
and CD8
+ cells express IL-17A and IL-17F mRNA (Fig-
ure 4). To our knowledge, this is the first definitive
demonstration that both CD4
+ and CD8
+ cells are cap-
able of expressing Th17 cytokines in COPD. COPD is
marked by increased number of T cells in lung parench-
yma and both peripheral and central airways, with a
greater increase in CD8
+ cells relative to CD4
+ T cells
[4]. A number of studies have attempted to characterize
the pattern of lymphocyte cytokine production in
COPD, but the results are conflicting [18,26]. Neverthe-
less, in the context of this observation it is noteworthy
that a recent study has reported that CD8
+ T cells are
activated in the presence of the cytokines IL-6 or IL-21
Figure 3 IL-17A and IL-17F mRNA expression in airways of COPD patients. (A) Quantitative RT-PCR was performed from frozen airways
sections of COPD patients. One representative example from 7 subjects with similar results is shown. (B) Quantification of IL-17A and IL-17F
mRNA expression in airways of control subjects and COPD patients. Results are expressed as means ± SEM. N = 7 for both control subjects and
COPD patients.
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+ and CD8
+ T cells in airways of
COPD patients. (A) Double immunofluorescence staining was performed. Scale bar = 5 μm. (B) Percentage of CD4
+ and CD8
+ T cells that
express IL-17A and IL-17F. Results are expressed as means ± SEM. (C) Percentage of CD4
+ and CD8
+ T cells that express IL-17A and IL-17F in
total IL-17A
+ and IL-17F
+ cells. Results are expressed as means ± SEM. *P < 0.05. N = 3 COPD patients. (D) IL-17A and IL-17F mRNA expression in
CD8
+ T cells in airways of COPD patients. Immunohistochemistry determined CD8
+ T cells were selected by LCM, and then RT-PCR was
performed to detect the mRNA expression of IL-17A and IL-17F. One representative result from 3 subjects is shown.
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Our findings also need to be taken seen in the context
of reports of Tc17 cells in a variety of immunological
diseases. For example, Tc17 have also been found in
cutaneous inflammatory diseases like psoriasis vulgaris
[27] and allergic contact dermatitis [28]. Tc17 cells may
also be important in defense against viruses [29,30].
The observation that expression of Th17 cytokines is
increased in COPD raises questions as to how this may
come about. The combination of IL-6 and TGF-b is
reported to skew the balance of T helper cells toward
Th17 cell differentiation [31]. In this regard, it is of
interest that increased production of IL-6 and TGF-b
has been reported in COPD patients [32], raising the
possibility that IL-6 and TGF-b may enable the promo-
tion of Th17 cells differentiation in COPD. Regardless
of the mechanism, Th17 cytokines have the potential to
contribute to COPD in various ways. IL-17A acts
directly on epithelial cells and on airway fibroblasts and
smooth muscle cells to induce the secretion of neutro-
phil-recruiting chemokines, such as CXCL8 [31].
Although a comprehensive comparative analysis of IL-
17F and IL-17A has not been performed, IL-17F appears
to have biological actions similar to IL-17A both in vitro
and in vivo [14]. Therefore it is possible that with acti-
vation of IL-17A and IL-17F mediated pathways, a
crosstalk between local activation of T cells and sus-
tained accumulation of neutrophils in inflamed airways
could be established. Zhu et al [33] have suggested that
biopsies from patients with chronic bronchitis have
more inflammation compared to patients with COPD
but without chorionic bronchitis. This group of patients
m i g h th a v em o r eI L - 1 7e x p r ession. However in our
study we did not group our subjects and presented the
data of our patients as one group according to GOLD
classification.
In summary, in bronchial biopsies we detected clear
evidence that the expression of the cytokines IL-17A
and IL-17F is increased in COPD compared to control.
In the case of IL-17F, this increased expression extends
to the epithelium and is not simply restricted to the
submucosa. Most importantly, we detected increased
expression of these cytokines in both CD4
+ and CD8
+
cells, suggesting that the inflammatory process in COPD
may resemble that in other disorders where Tc17 cells
are active. These findings contribute to the growing
body of information that supports the importance of
investigating the role of IL-17 and related cytokines in
COPD, potentially providing novel therapeutic targets in
this important chronic disease.
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